IMMUNOVANT, INC. Cash and Restricted Cash
IMMUNOVANT, INC. (IMVT) had Cash and Restricted Cash of $797.80 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $797.80M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $902.11M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $994.52M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $521.87M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $797.80M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $902.11M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $994.52M 10-Q · filed 2026-02-06 |
| 2025-09-30 | $521.87M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $598.91M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $713.97M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $374.69M 10-Q · filed 2026-02-06 |
| 2024-09-30 | $472.94M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $560.00M 10-Q · filed 2025-08-11 |
| 2024-03-31 | $635.37M 10-K · filed 2026-05-20 |
| 2023-12-31 | $690.94M 10-Q · filed 2025-02-06 |
| 2023-09-30 | $269.93M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $329.96M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $376.53M 10-K · filed 2026-05-20 |
| 2022-12-31 | $432.61M 10-Q · filed 2024-02-12 |
| 2022-09-30 | $405.77M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $427.20M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $493.82M 10-K · filed 2025-05-29 |
| 2021-12-31 | $527.00M 10-Q · filed 2023-02-03 |
| 2021-09-30 | $558.95M 10-Q · filed 2022-11-04 |
| 2021-06-30 | $379.00M 10-Q · filed 2022-08-05 |
| 2021-03-31 | $400.15M 10-K · filed 2023-05-22 |
| 2020-12-31 | $421.97M 10-Q · filed 2022-02-04 |
| 2020-09-30 | $444.37M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $280.28M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $100.57M 10-K · filed 2022-06-08 |
| 2019-12-31 | $123.53M 10-Q · filed 2021-02-16 |
| 2019-09-30 | $18.99M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $3.96M 10-Q · filed 2020-08-12 |
| 2019-03-31 | $6.99M 10-K · filed 2021-06-01 |
| 2018-12-31 | $12.10M 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |